TBRG Quote, Financials, Valuation and Earnings

LENZ Therapeutics has a net margin of -3.37% compared to TruBridge's net margin of --. TruBridge's return on equity of -11.47% beat LENZ Therapeutics's return on equity of --.

TruBridge has a consensus price target of $29.25, signalling upside risk potential of 4.06%. On the other hand LENZ Therapeutics has an analysts' consensus of $42.63 which suggests that it could grow by 66.24%. Given that LENZ Therapeutics has higher upside potential than TruBridge, analysts believe LENZ Therapeutics is more attractive than TruBridge.

TruBridge has a beta of 0.713, which suggesting that the stock is 28.717% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

TruBridge has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. TruBridge pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.

TruBridge quarterly revenues are $90.8M, which are larger than LENZ Therapeutics quarterly revenues of --. TruBridge's net income of -$3.1M is higher than LENZ Therapeutics's net income of -$12.7M. Notably, TruBridge's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TruBridge is 1.17x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

LifeMD has a net margin of -3.37% compared to TruBridge's net margin of -0.17%. TruBridge's return on equity of -11.47% beat LifeMD's return on equity of --.

TruBridge has a consensus price target of $29.25, signalling upside risk potential of 4.06%. On the other hand LifeMD has an analysts' consensus of $11.94 which suggests that it could grow by 121.2%. Given that LifeMD has higher upside potential than TruBridge, analysts believe LifeMD is more attractive than TruBridge.

TruBridge has a beta of 0.713, which suggesting that the stock is 28.717% less volatile than S&P 500. In comparison LifeMD has a beta of 1.505, suggesting its more volatile than the S&P 500 by 50.535%.

TruBridge has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TruBridge pays -- of its earnings as a dividend. LifeMD pays out -16.45% of its earnings as a dividend.

TruBridge quarterly revenues are $90.8M, which are larger than LifeMD quarterly revenues of $64.3M. TruBridge's net income of -$3.1M is lower than LifeMD's net income of -$106.3K. Notably, TruBridge's price-to-earnings ratio is -- while LifeMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TruBridge is 1.17x versus 1.06x for LifeMD. Usually stocks with elevated PS ratios are considered overvalued.

Veradigm has a net margin of -3.37% compared to TruBridge's net margin of --. TruBridge's return on equity of -11.47% beat Veradigm's return on equity of --.

TruBridge has a consensus price target of $29.25, signalling upside risk potential of 4.06%. On the other hand Veradigm has an analysts' consensus of $10.00 which suggests that it could grow by 135.29%. Given that Veradigm has higher upside potential than TruBridge, analysts believe Veradigm is more attractive than TruBridge.

TruBridge has a beta of 0.713, which suggesting that the stock is 28.717% less volatile than S&P 500. In comparison Veradigm has a beta of 0.564, suggesting its less volatile than the S&P 500 by 43.599%.

TruBridge has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veradigm offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TruBridge pays -- of its earnings as a dividend. Veradigm pays out -- of its earnings as a dividend.

TruBridge quarterly revenues are $90.8M, which are larger than Veradigm quarterly revenues of --. TruBridge's net income of -$3.1M is higher than Veradigm's net income of --. Notably, TruBridge's price-to-earnings ratio is -- while Veradigm's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TruBridge is 1.17x versus 0.89x for Veradigm. Usually stocks with elevated PS ratios are considered overvalued.

Streamline Health Solutions has a net margin of -3.37% compared to TruBridge's net margin of -56.03%. TruBridge's return on equity of -11.47% beat Streamline Health Solutions's return on equity of -54.79%.

TruBridge has a consensus price target of $29.25, signalling upside risk potential of 4.06%. On the other hand Streamline Health Solutions has an analysts' consensus of $22.50 which suggests that it could fall by -51.44%. Given that TruBridge has higher upside potential than Streamline Health Solutions, analysts believe TruBridge is more attractive than Streamline Health Solutions.

TruBridge has a beta of 0.713, which suggesting that the stock is 28.717% less volatile than S&P 500. In comparison Streamline Health Solutions has a beta of 1.774, suggesting its more volatile than the S&P 500 by 77.435%.

TruBridge has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Streamline Health Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TruBridge pays -- of its earnings as a dividend. Streamline Health Solutions pays out -- of its earnings as a dividend.

TruBridge quarterly revenues are $90.8M, which are larger than Streamline Health Solutions quarterly revenues of $4.4M. TruBridge's net income of -$3.1M is lower than Streamline Health Solutions's net income of -$2.5M. Notably, TruBridge's price-to-earnings ratio is -- while Streamline Health Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TruBridge is 1.17x versus 0.65x for Streamline Health Solutions. Usually stocks with elevated PS ratios are considered overvalued.